In contrast, the influence of CYP3A5*3 pharmacogenetics was found to be lacking towards first-line antihypertensives for CKD, namely angiotensin converting enzyme inhibitor (ACEI) and angiotensin II blocker (ARB) [6]. This evidence concerns the gene AGT and chronic kidney disease.